

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

for
Permanent Record
and the
Appointments and Promotions Committee

Date Prepared: July 24, 2023

Name: Zachary James Reitman, MD, PhD

Primary academic appointment: Radiation Oncology

Primary academic department: Radiation Oncology

Present academic rank and title: Assistant Professor of Radiation Oncology

Date and rank of first Duke Faculty appointment: August 1, 2019 Medical Instructor

Medical Licensure:

North Carolina License #201900924, issued April 10, 2019, current

Virginia License #0101269602, issued May 12, 2020, current

Specialty Board Certification:

Radiation Oncology, May 19, 2021, participating in MOC

Date of birth: January 22, 1984

Place: Coatesville, PA USA

Citizen of: United States

Education:

Downingtown High School	Downingtown, PA	2002	
The Pennsylvania State University Schreyer Honors College	University Park, PA	2006	B.S., Biochemistry and Molecular Biology
Duke University Graduate School	Durham, NC	2012	Ph.D., Pathology
Duke University School of Medicine	Durham, NC	2014	M.D.

Professional training and academic career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Union Memorial Hospital, Baltimore, MD	Internal Medicine Intern	06/13/2014 – 06/30/2015
Harvard Radiation Oncology Program at Massachusetts General Hospital and Brigham and Women's Hospital, Boston, MA	Resident Physician	07/01/2015 – 06/30/2019
Duke University School of Medicine	Medical Instructor in Radiation Oncology	08/01-2019- 6/30/2021
Duke University School of Medicine	Assistant Professor in Radiation Oncology	07/01/2021- present
Duke University School of Medicine	Assistant Professor in Pathology (secondary appointment)	06/01/2022- present
Duke University School of Medicine	Assistant Professor in Neurosurgery (secondary appointment)	06/01/2022- present

Publications:**1. Peer-refereed journals:****i. Original research articles**

1. Shen M*, **Reitman ZJ***, Zhao Y, Moustafa I, Wang Q, Arnold JJ, Pathak HB, Cameron CE. Picornavirus genome replication: Identification of the surface of the poliovirus (PV) 3C dimer that interacts with PV 3Dpol during VPg uridylylation and construction of a structural model for the PV 3C₂-3Dpol complex (2008). *J Biol Chem.* 283(2):875–888 PMID: 17993457 *Equal contributor
2. Lopez GY, **Reitman ZJ**, Solomon D, Waldman T, Bigner DD, McLendon RE, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain (2010). *Biochem Biophys Res Commun.* 398(3):585-7 PMID: 20603105
3. Jin G*, **Reitman ZJ***, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H. 2-Hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP⁺-dependent isocitrate dehydrogenase mutations (2011). *PLoS One* 6(2):e16812 PMID: 21326614 *Equal contributor
4. **Reitman ZJ***, Jin G*, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome (2011). *Proc Natl Acad Sci (USA)* 108(8):3270-5 PMID: 21289278 *Equal contributor

5. Riggs KJ, **Reitman ZJ**, Milenz TJ, Goodman PC. Relationship between time of first publication and subsequent publication success among non-PhD physician-scientists (2012). *J Grad Med Ed.* 4(2): 196-201 PMID: 23730441
6. Jiao Y*, Killela PJ*, **Reitman ZJ***, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosenberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettgowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas (2012). *Oncotarget* 3(7):709-22 PMID: 22869205 Cover feature *Equal contributor
7. **Reitman ZJ**, Choi BD, Spasojevic IS, Sampson JH, Yan H. Enzyme redesign guided by cancer-derived IDH1 mutations (2012). *Nature Chem Biol* 8(11):887-9 PMID: 23001033 **Cover feature**
8. Jin G*, **Reitman ZJ***, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas (2013). *Cancer Res* 73(2):496-501 PMID: 23204232 *Equal contributor
9. Killela PJ*, **Reitman ZJ***, Jiao Y*, Bettgowda C*, Agrawal N, Diaz LA Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal (2013). *Proc Natl Acad Sci (USA)* 110(15):6021-6 PMID: 23530248 *Equal contributor
10. Bettgowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, **Reitman ZJ**, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N. Exomic sequencing of four rare central nervous system tumor types (2013). *Oncotarget.* 4(4):572-83 PMID: 23592488
11. Killela PJ, Pirozzi CJ, Healy P, **Reitman ZJ**, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas (2014). *Oncotarget* 5(6):1515-25 PMID: 24722048
12. Killela PJ*, Pirozzi CJ*, **Reitman ZJ***, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma (2014). *Oncotarget.* 5(6):1452-7. PMID: 24140581 *Equal contributor
13. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, Hao S, Wang Y, Webb JB, Friedman HS, Friedman AH, McLendon RE, He Y, **Reitman ZJ**†, Bigner DD, Yan H†. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas (2014). *Nature Genetics.* 46(7):726-30 PMID: 24880341 †Corresponding author
14. **Reitman ZJ**, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, Spasojevic I, Boros LG, Yang SH, Yan H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia (2014). *J Biol Chem.* 22;289(34):23318-28 PMID: 24986863

15. **Reitman ZJ**, Sinenko SA, Spana EP, Yan H. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in *Drosophila* (2015). *Blood*. 125(2):336-45 PMID: 25398939
16. Chitneni SK, **Reitman ZJ**, Gooden DM, Yan H, Zalutsky MR. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs (2016). *Eur J Med Chem*. 119:218-30 PMID: 27163884
17. Song ZJ*, **Reitman ZJ***, Ma ZY*, Chen JH*, Zhang QL*, Shou XF*, Huang CX, Wang YF, Li SQ, Mao Y, Zhou LF, Lian BF, Yan H, Shi YY, Zhao Y. The genome-wide mutational landscape of pituitary adenomas (2016). *Cell Res*. 26(11):1255-1259 PMID: 27670697 *Equal contributor
18. Cagney DN, Martin AM, Catalano PJ, **Reitman ZJ**, Mezocho GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. (2018) *Radiotherapy and oncology*. 126(3):511-518. PMID: 29398153
19. Chitneni SK, **Reitman ZJ**, Spicehandler R, Gooden DM, Yan H, Zalutsky MR. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. (2018) *Bioorganic & medicinal chemistry letters*. 28(4):694-699. PMID: 29366652 PMCID: PMC5817038
20. **Reitman ZJ***, Paoletta BR*, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmer L, Herbert ZT, Sun Y, Weatherbee JL, Alberta J, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA, Haas-Kogan D, Filbin MG, Suva ML, Regev A, Stiles C, Kieran MW, Goumnerova L, Ligon KL, Shalek AK, Bandopadhyay P, Beroukhim R. Mitogenic and progenitor gene programs in single pilocytic astrocytoma cells (2019). *Nat Commun*. 10(1):3731. PMID: 31427603 *Equal contributor
21. Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, **Reitman ZJ**, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas (2021). *Clin Cancer Res*. 27(24):6800-6814 PMID: 34593527
22. Deland K, Mercer JS, Crabtree DM, Garcia MEG, Reinsvold M, Campos LDS, Williams NT, Luo L, Ma Y, **Reitman ZJ**, Becher OJ, Kirsch DG. Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiotherapy (2022). *Int J Radiat Oncol Biol Phys*. 112(3):771-779 PMID: 34619331
23. Khadka P*, **Reitman ZJ***, Lu S, Buchan G, Gionet G, Dubois F, Carvalho DM, Shih J, Zhang S, Greenwald NF, Zack T, Shapira O, Pelton K, Hartley R, Bear H, Georgis Y, Jarmale S, Schoolcraft K, Miller PG, Condurat AL, Gonzalez E, Qian K, Morin E, Langhnoja J, Lupien L, Rendo V, Digiacomio J, Wang D, Zhou K, Kumbhani R, Guerra Garcia ME, Sinai CE, Becker S, Schneider R, Vogelzang J, Melanson R, Keshishian H, Goodale A, Abid T, Kalani Z, Persky NS, Piccioni F, Root DE, Carcaboso AM, Carr SA, Ebert BL, Fuller C, Kieran MW, Jones C, Ligon KL, Beroukhim R, Phoenix TN, Bandopadhyay P. *PPMID* mutations are oncogenic drivers of *de novo* Diffuse Midline Glioma formation (2022). *Nat Commun*. 13(1):604 PMID: 35105861 ***Equal contributor**
24. Low JT, Chandramohan V, Bowie ML, Brown MC, Waitkus MS, Briley A, Stevenson K, Fuller R, **Reitman ZJ**, Muscat AM, Hariharan S, Hostettler J, Danehower S, Baker A, Khasraw M, Wong NC, Gregory S, Nair SK, Heimberger A, Gromeier M, Bigner DD, Ashley DM. Epigenetic STING

silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. *Cancer Cell*. 2022 May 9;40(5):439-440. doi: 10.1016/j.ccell.2022.04.009. Epub 2022 Apr 28. PMID: 35487217.

25. Carpenter DJ, Fairchild AT, Adamson JD, Fecci PE, Sampson JH, Herndon JE, Torok JA, Mullikin TC, Kim GJ, **Reitman ZJ**, Kirkpatrick JP, Floyd SR. Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery. *Adv Radiat Oncol*. 2022 Dec 29;8(2):101166. doi: 10.1016/j.adro.2022.101166. PMID: 36845614; PMCID: PMC9943776.
26. Carpenter DJ, Natarajan B, Arshad M, Natesan D, Schultz O, Moravan MJ, Read C, Lafata KJ, Giles W, Fecci P, Mullikin TC, **Reitman ZJ**, Kirkpatrick JP, Floyd SR, Chmura SJ, Hong JC, Salama JK. Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study. *Cancers (Basel)*. 2022 Oct 22;14(21):5186. doi: 10.3390/cancers14215186. PMID: 36358606; PMCID: PMC9657742.
27. Stewart CE, Guerra-García ME, Luo L, Williams NT, Ma Y, Regal JA, Ghosh D, Sansone P, Oldham M, Deland K, Becher OJ, Kirsch DG, **Reitman ZJ**. The Effect of *Atm* Loss on Radiosensitivity of a Primary Mouse Model of *Pten*-Deleted Brainstem Glioma. *Cancers (Basel)*. 2022 Sep 17;14(18):4506. doi: 10.3390/cancers14184506. PMID: 36139666; PMCID: PMC9496888.
28. Weidenhammer LB, Liu HQ, Luo L, Williams NT, Deland K, Kirsch DG, **Reitman ZJ**. Inducing primary brainstem gliomas in genetically engineered mice using RCAS/TVA retroviruses and Cre/loxP recombination. *STAR Protoc*. 2023 Feb 13;4(1):102094. doi: 10.1016/j.xpro.2023.102094. Epub ahead of print. PMID: 36853662; PMCID: PMC9950926.
29. Natesan D, Carpenter DJ, Giles W, Oyekunle T, Niedzwiecki D, **Reitman ZJ**, Kirkpatrick JP, Floyd SR. Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases. *Adv Radiat Oncol*. 2023 Mar 8;8(4):101211. doi: 10.1016/j.adro.2023.101211. PMID: 37152484; PMCID: PMC10157109.
30. Regal JA, Guerra García ME, Jain V, Chandramohan V, Ashley DM, Gregory SG, Thompson EM, López GY, **Reitman ZJ**. Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. *Acta Neuropathol Commun*. 2023 Mar 25;11(1):50. doi: 10.1186/s40478-023-01548-3. PMID: 36966348; PMCID: PMC10039537.
31. Floyd W, Carpenter D, Vaios E, Shenker R, Hendrickson P, Adamson JD, Giles WM, Wang C, Allen K, Mullikin T, Floyd SR, Kirkpatrick JP, Green M, **Reitman ZJ** (in press). "Impact of ATM Variants on Radionecrosis and Local Control after Stereotactic Radiosurgery for Non Small Cell Lung Cancer Brain Metastases." 2023. *Adv Radiat Oncol*.

ii. Letters

1. **Reitman Z**, Yan H. IDH1 and IDH2 mutations in gliomas (2009). Author reply. *N Engl J Med*. 360:2248-2249.
2. **Reitman ZJ**, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 mutations are not found in canine glioma (2010). Letter to the editor. *Int J Cancer*. 127(1):245-6 PMID: 19877121

iii. Editorials

1. **Reitman ZJ**, Pirozzi CJ, Yan H. Promoting a new brain tumor mutation: TERT mutations in CNS tumors (2013). Editorial. *Acta Neuropathol*. 126(6):789-92 PMID: 24217890

2. **Reitman ZJ**. Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma (2014). Editorial. *Pharmacogenomics*. 15(13):1639-41. PMID: 25410889
3. **Reitman ZJ**, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes (2010). Preview. *Cancer Cell*. 17(3):215-6 PMID: 20227034
4. Pirozzi CJ, **Reitman ZJ**, Yan H. Releasing the block: setting differentiation free with IDH inhibitors (2013). Preview. *Cancer Cell*. 23(5):570-2 PMID: 23680144

iv. **Reviews**

1. **Reitman ZJ**, Yan H. IDH1 and IDH2 mutations in glioma: alterations at a crossroads of cellular metabolism (2010). Review. *JNCI*. 102(13):932-41 PMID: 20513808
2. **Reitman ZJ**, Winkler FW, Elia AE. New directions in the treatment of glioblastoma. (2018). Review. *Seminars in Neurology*. 38(1):50-60. PMID: 29548052
3. Guerra Garcia ME, Kirsch DG, **Reitman ZJ**. Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. (2022). Review. *Seminars in Radiation Oncology*. 32(1):3-14 PMID: 34861994
4. Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, Painter BD, **Reitman ZJ**, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. *Front Oncol*. 2022 Jan 25;11:785064. doi: 10.3389/fonc.2021.785064. PMID: 35145903; PMCID: PMC8821807.
5. Vaios EJ, Winter SF, Shih HA, Dietrich J, Peters KB, Floyd SR, Kirkpatrick JP, **Reitman ZJ**. Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy. *Cancers (Basel)*. 2023 Apr 24;15(9):2432. doi: 10.3390/cancers15092432. PMID: 37173897; PMCID: PMC10177360.

2. **Chapters in books:**

1. **Reitman ZJ**, Yan H. Malignant glioma: isocitrate dehydrogenase 1 and 2 mutations (in press). (2011) In Hayat MA (ed.) *Tumors of the Central Nervous System*. 2:53-62. Springer

3. **Non-refereed publications:**

None

4. **Published scientific reviews for mass distribution**

None

Patents:

1. Yan H, Bigner D, Killela P, **Reitman Z**. Mutations define clinical subgroups of gliomas. US Application Serial Number 15/115,044. Filed as PCT International Application PCT/US2016/012888 on 26 January 2015. US patent application filed 28 July, 2016.
2. Yan H, Bigner D, He Y, Jin G, **Reitman Z**. Effects of IDH1 and IDH2 mutations on the cellular metabolome. US 20120202883, Non-provisional patent application filed Jan. 20, 2012. US Patent assigned 8 April, 2014.
3. **Reitman ZJ**, Yan H, Choi DB, Sampson JH. Novel oxidoreductases for enantioselective reactions. US 20130266998, Non-provisional patent application filed Feb. 27, 2013. US Patent assigned 13 May, 2013.

Scholarly societies:

Phi Beta Kappa	2006-
Radiation Research Society (RRS)	2018-
American Society for Clinical Oncology (ASCO)	2017-
Radiological Society of North America (RSNA), Trainee Member	2017-
Association of Residents in Radiation Oncology (ARRO), Member	2015 - 2019
American Society for Radiation Oncology (ASTRO)	2015-
Member, Duke Cancer Institute	2019-
American Association for Cancer Research (AACR)	2021-

Professional awards and special recognitions:

Resident Clinical Teaching Award, Radiation Oncology	2023
Early Career Investigator Travel Award, International Congress of Radiation Research	2023
Duke University Nominee, Pew-Stewart Cancer Research Scholar Award	2022
St. Baldrick's Foundation Fellow	2020-2023
Defeat DIPG ChadTough SoSo Strong New Investigator Award	2020-2021
Pediatric Brain Tumor Foundation Early Career Development Award	2019-2022
Defeat DIPG ChadTough Fellow	2018-2019
Conquer Cancer Foundation of ASCO Young Investigator Award	2018-2019
American Board of Radiology Leonard Holman Research Pathway	2016-2019
Cancer Biology NRSA Training Grant (T32-CA059365-15)	2012-2013
Med. Sci. Training Program NRSA Training Grant (T32-GM007171-35)	2006-2010
Days of Molecular Medicine Conference Travel Award	2009
Department of Homeland Security Scholar (full tuition, stipend)	2004-2006
Barry M. Goldwater Scholar (tuition)	2004-2006
Penn State Schreyer Honors College Scholar (tuition)	2002-2006
American Association for Cancer Research Bardos Travel Award	2004-2005
Wistar Institute Summer Undergraduate Research Fellowship	2003

Editorial Experience

i. Ad Hoc scientific review journals

1. Science Reports
2. Neuro-Oncology
3. PLoS One
4. Tumor Biology
5. Journal of Pediatric Genetics
6. Molecular Cancer Therapeutics
7. Future Oncology
8. Future Medicinal Chemistry
9. Oncotarget
10. British Journal of Cancer
11. Journal of Translational Medicine
12. Neuro Oncology Advances
13. Clinical Translational Medicine
14. Frontiers in Oncology
15. Gene Reports
16. International Journal of Radiation Oncology Biology Physics
17. Oncogene
18. Radiation Oncology Advances
19. Clinical and Translational Medicine
20. Journal of Radiosurgery and SBRT

21. New England Journal of Medicine (under mentorship of Hai Yan)
22. Science (under mentorship of Hai Yan)
23. Science Translational Medicine (under mentorship of Hai Yan)
24. Lancet Oncology (under mentorship of Hai Yan)
25. Cancer Cell (under mentorship of Hai Yan)
26. Cancer Research (under mentorship of Hai Yan)
27. Acta Neuropathologica (under mentorship of Hai Yan)
28. Neuropathology and Applied Neurobiology (under mentorship of Hai Yan)
29. BBSRC (UK Funding Agency) (under mentorship of Hai Yan)

30. Neuro-Oncology (under mentorship of Rameen Beroukhim)
31. Genome Medicine (under mentorship of Rameen Beroukhim)
32. Cancer Cell (under mentorship of Rameen Beroukhim)

33. Nature Communications (under mentorship of Pratiti Bandopadhyay)

34. Theranostics (under mentorship of David Kirsch)
35. Nature Communications (under mentorship of David Kirsch)

Ad Hoc Review assignments for funding organizations

1. Reviewer for St. Baldrick’s Fellowship Grant Extension Competitive Applications, May 18, 2022
2. Duke Cancer Institute 2022 Spring Pilot Awards, May 20, 2022
3. Duke Cancer Institute 2022 Fall Pilot Awards, Oct 20, 2022
4. Reviewer for St. Baldrick’s Foundation Scholar Applications, March 9, 2023
5. *Ad hoc* reviewer, NIH Scientific Review Group ZCA1 RTRB-B M1 R, SEP-8: NCI Clinical and Translational Research R03 and R21 applications, March 2023
6. Reviewer for Children with Cancer UK funding, April 13, 2023
7. Reviewer for CURE Pediatric Brain Cancer, May 22, 2023

Organizations and participation:

- Session Co-Chair, “Imaging and Circulating Biomarkers of Radiation Response,”
Radiation Research Society Annual Meeting 2018
- Session Co-Chair, “Drug Radiation Combinations,” Radiation Research Society Annual Meeting
2020
- Session Co-Chair, “Spine Stereotactic Radiation Therapy Fractionation Session,” Duke Center for
Brain and Spine Metastases Inaugural Colloquium 2021
- Session Co-Chair, “Multi-Modality management of spinal metastases – novel approaches in the IO
era,” Duke Center for Brain and Spine Metastases 2nd Annual Colloquium 2022

External support - gifts, grants, and contracts:

	<u>PI</u>	<u>% Effort</u>	<u>Purpose</u>	<u>Approximate Amount</u>	<u>Duration</u>
a) Past:					
			Joint Centers for Radiation Therapy Foundation Funds		
			“Identifying therapeutic susceptibilities in PPM1D-mutated diffuse intrinsic pontine glioma”		
			Reitman, Chowdhury, and Bandopadhyay		

Effort as needed Research funds \$30,000 3/2019 – 6/2019

Conquer Cancer Foundation of ASCO Young Investigator Award

“Identifying therapeutic dependencies in PPM1D-mutated diffuse intrinsic pontine glioma”

Reitman 25% Research \$50,000 7/2018-6/2019

Defeat DIPG ChadTough Fellowship

“Prioritizing PPM1D mutations as a target for new DIPG therapies”

Reitman 50% Salary \$100,000 12/2017-12/2019

P50-CA190991 (Sampson)

09/24/2014-08/31/2024

NIH

Duke SPORE in Brain Cancer: The OVERALL GOAL is to develop or improve new or existing therapies that will prolong the quality and length of life of patients with primary malignant brain tumors through a better understanding of the biology of these tumors and the patient’s response to the tumor and the therapy as well as by attracting new investigators. This SPORE includes three Projects, four supporting Cores, and Career Enhancement (CEP) and Developmental Research Programs (DRP).

Stimulating the immune microenvironment in brainstem gliomas (Reitman)

09/01/2019-08/31/2020

Career Enhancement Project

Reitman 10% Research \$50,000 9/2019-8/2020

Defeat DIPG ChadTough SoSo Strong Foundation New Investigator Award

“Enhancing the efficacy of radiation therapy for DIPG”

Reitman 30% Research \$250,000 1/2020-12/2021

Duke Cancer Institute Fall Pilot Award

“Revealing the transcriptional landscape of glioneuronal tumors at single cell resolution”

Reitman Effort as needed Research \$50,000 1/2020-12/2021

Fund to Retain Clinical Researchers

“Revealing the transcriptional landscape of gangliogliomas at single cell resolution”

Reitman Effort as needed Technician Salary \$44,000 1/2020-12/2021

P50-CA190991 (Sampson)

09/24/2014-08/31/2024

NIH

Duke SPORE in Brain Cancer: The OVERALL GOAL is to develop or improve new or existing therapies that will prolong the quality and length of life of patients with primary malignant brain tumors through a better understanding of the biology of these tumors and the patient’s response to the tumor and the therapy as well as by attracting new investigators. This SPORE includes three Projects, four supporting Cores, and Career Enhancement (CEP) and Developmental Research Programs (DRP).

Reducing toxicity and increasing survival for pediatric brain tumor patients with ultra high dose rate FLASH radiation therapy (Reitman and Kirsch)

09/01/2019-08/31/2021

Developmental Research Project

Reitman 10% Research \$100,000 9/2019-8/2021

St. Baldrick’s Foundation Fellowship

“Identifying subtypes of brainstem gliomas that can be radiosensitized by ATM inhibition”
 Reitman 1% Salary \$197,000 7/2020-6/2022

St. Baldrick’s Foundation Fellowship
 Competitive renewal for 3rd year of funding

“Identifying subtypes of brainstem gliomas that can be radiosensitized by ATM inhibition”
 Reitman 50% Research \$98,500 7/2022-6/2023

b) Present:

NCI K08 CA256045-A01 Mentored Clinician Scientist Career Development Award
 “Enhancing the efficacy of radiation therapy for brainstem glioma by targeting ATM”
 Reitman 75%* Research \$1,118,109 8/2022-7/2027
 *Effort approved to be complementary with St. Baldrick’s, Pediatric Brain Tumor
 Foundation, and Defeat DIPG awards.

Additional project supplement for NCI K08 CA256045-A01:
 Administrative Supplement to Promote Research Continuity and Retention of NIH
 Mentored Career Development (K) Award Recipients (NOT-OD-23-031)
 Reitman 0% Research \$53,357 8/2023-7/2024

Pediatric Brain Tumor Foundation Early Career Development Award
 “Identifying subtypes of brainstem gliomas that can be radiosensitized by ATM inhibition”
 Reitman 1%* Research \$300,000 9/2019-8/2023
 *complementary effort with K08CA256045

Additional one-time Pediatric Brain Tumor Foundation supplement for multi-omic
 analysis of mouse brain tumor models
 Reitman N/A Research \$52,000 1/2023

Defeat DIPG ChadTough Foundation New Investigator Award
 “Dissecting mechanisms of resistance in DIPG”
 Reitman 1% Research \$250,000 7/2022-6/2024
 *complementary effort with K08CA256045

NCI P50-CA190991 (PI: Sampson)
 09/24/2014-08/31/2024
 NIH

Duke SPORE in Brain Cancer: The OVERALL GOAL is to develop or improve new or existing therapies
 that will prolong the quality and length of life of patients with primary malignant brain tumors through a
 better understanding of the biology of these tumors and the patient’s response to the tumor and the therapy as
 well as by attracting new investigators. This SPORE includes three Projects, four supporting Cores, and
 Career Enhancement (CEP) and Developmental Research Programs (DRP).

Stimulating innate immune signaling in Glioblastoma by perturbing STING (Reitman and Low)
 09/01/2022-08/31/2024
 Developmental Research Project
 Reitman 1% Research \$100,000 9/2022-8/2024

NCI U19-CA264385-01 (PI: Ashley)
 Glioblastoma Therapeutics Network

“6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification”

Role: Provide primary mouse brain tumor model and radiation oncology expertise

Ashley 5% Research \$3,159,725 9/2021-8/2026

Startup funds and salary backstop funds

From Departments of Radiation Oncology, Neurosurgery and Brian Tumor Center

Reitman As needed Research and salary Does not expire

Botha Family Philanthropic Funds

“BRAF-mutated brain tumor consortium”

Role: One of seven PIs at Duke, UCSF, and Dana-Farber, I will carry out multi-omic analyses on mouse and human BRAF-mutated gliomas

Reitman 1% Research \$441,000 7/2022-6/2025

c) Pending:

Applications for funding support have been submitted for an Alex's Lemonade Stand Foundation Award, and for the Duke SPARK Award.

Additional applications for funding are in various stages of preparation and submission.

Mentoring activities

- i. Residents mentored on clinical projects
 - a. Eugene Vaios, MD, MBA – 2021 (A. retrospective analysis of patients receiving dual immune checkpoint blockade and stereotactic radiosurgery for brain metastases; B. retrospective analysis of PCNSL patients treated with whole brain radiation therapy with SRS boost). Co-mentor on Duke R38 Research Pathway award
 - b. David Carpenter – ATM mutations and SRS outcomes
 - c. Jim Leng, MD – TP53 mutations and SRS outcomes
 - d. Mark Chen, MD, PhD – KEAP1 mutations and SRS outcomes
- ii. Research year residents
 - a. Joshua Regal, MD, PhD – 2021-present (PGY5 research on single cell RNA-sequencing of pediatric gliomas)
- iii. Graduate students
 - a. Patrick Killela – 2010-2014 (mentored this junior graduate student while I was a senior graduate student and postdoc in Yan Lab)
 - b. Prasidda Khadka – 2017-2019 (during Dana-Farber Cancer Institute post-doc)
- iv. Thesis committees
 - a. Lam Lay – 2020-2021 (Thesis committee member, Physics MS student at Duke)
 - b. Jingtong Zhao – 2022-2023 (Thesis committee member, Physics MS student at Duke)
 - c. Lucy Driver – 2023-present (Thesis committee member, Pathology PhD student at Duke)
- v. Medical students
 - a. Michael McCormick – 2010-2011 (while graduate student in Yan Lab)
 - b. Bronwen Foreman – 2021-present (retrospective analysis of PCNSL patients treated with whole brain radiation therapy with SRS boost)
 - c. Danielle Burner – 2022-2023 – associations between radionecrosis and gene variants seen on tumor genotyping reports
- vi. Research technicians
 - a. Graham Buchan – 2017-2019 (during Dana-Farber Cancer Institute post-doc)

- b. Maria Guerra Garcia – 2019-2022, then matriculated into PhD program at Washington University in St. Louis
- c. Connor Stewart – 2020-2022, then matriculated into PhD program at Emory
- d. Loren Weidenhammer – 2021-2023, then matriculated into PhD in Pathology at Duke
- e. Harrison Liu – 2022-present
- f. Joshua Tolliver – 2023-present
- vii. Undergraduate students
 - a. Kevin Tu, Summer AMGEN Research Scholar, University of Maryland Baltimore County – summer 2022
 - b. Sophie Wu, Duke University – Undergraduate research associate - Jan 2022-present
 - c. Debosir Ghosh, Duke University – Undergraduate research associate - Jan 2022-July 2023
 - d. Abby Groth - Undergraduate research associate – May 2023-present

Education / Teaching activities

- Teaching and supporting Learners in the Clinic
 - a) Residents on 3-month CNS radiation oncology rotations
 - i) Eugene Vaios, MD, MBA – July-Aug 2020
 - ii) Joshua Regal, MD, PhD – Jan-Mar 2021
 - iii) Rachel Shenker, MD – Apr-Jun 2021
 - iv) Scarlett Acklin, MD – Apr-Jun 2022
 - v) Alex Diaz, MD, PhD – Jul-Sept 2022
 - vi) Dominic LaBella MD – Oct-Dec 2022
 - vii) Mark Chen MD, PhD – Jan-Mar 2023
 - viii) Jim Leng, MD – Apr-Jun 2023
 - ix) Pooja Karukonda, MD – July-Sep 2023
 - b) Education Champion on CNS radiation oncology rotation (not clinically covered by resident, but carry out weekly 30-60 minute didactic sessions)
 - i) Collin Kent, MD – July-Aug 2021
 - ii) Divya Natesan, MD – Sep-Dec 2021
 - c) Medical students on 1-day rotations in my clinic as part of month-long RO rotations, approximately 10 per year. 2020-present
 - d) Neuro-Oncology and Neurosurgery fellows, approximately 6 fellows a year for 2-4 weekly clinic days each. 2020-present
 - e) Undergraduate and premedical students
 - i) Sophie Wu, Undergraduate shadowing, Summer 2022 – present
 - ii) Debosir Ghosh, Undergraduate shadowing, Summer 2022 – present
 - iii) Harrison Liu, Undergraduate shadowing, Summer 2022 - present
- Development of courses/educational programs
 - a) Molecular Cancer Biology 818: 90 minute lecture on “Cancer Genomics” Oct 2021, Oct 2022, Oct 2023
 - b) Duke Radiation Oncology Residency weekly CNS didactics 2020-present
 - c) Duke Radiation Oncology Residency Radiation Biology course lecture 2020-present
 - d) Harvard Radiation Oncology Program Admissions Committee 2015-2016
 - e) Oakstone Radiation Oncology Review: Adult Brain Tumors 2020
- Development of assessment tools and methods
 - a) MedStar Hospitals EMR Improvement Committee 2014-2015
- Education management/ Leadership
 - a) Duke Medical Scientist Training Program Annual Symposium Organizer 2010
 - b) Duke University School of Medicine 3rd Year Medical Student Mentor, Term Mentor connected to Prof. David Kirsch as senior mentor
 - c) Harvard Radiation Oncology Program Resident Curriculum Co-Chair 2018-2019
 - d) Harvard Radiation Oncology Program Visiting Professor Co-Chair 2018-2019
 - e) Medical Scientist Training Program Admissions Committee 2023-present

Invited Lectures and Presentations

- i. International Meetings
 1. **Reitman ZJ.** Genomic analyses of glioblastoma, and understanding the results (2009). Lecture. 6 Sept. European Genetics Foundation. Course in the genetic basis of brain tumors. Bologna, Italy.
 2. **Reitman ZJ.** Genome-wide analysis of brain tumors (2009). Workshop. 6 Sept. European Genetics Foundation. Course in the genetic basis of brain tumors. Bologna, Italy.
- ii. National Scientific Meetings (invited)
 1. **Reitman ZJ.** *Global and targeted approaches to analyze the glioma metabolome (2011).* Speaker #7. 4 April. Neuro Tumor Club Dinner Meeting. Orlando, FL.
 2. **Reitman ZJ,** Jin G*, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Metabolomic profiling of a glioma cell line expressing IDH1 and IDH2 mutants (2011). Oral presentation #0085. 19-20 May. Society for Neuro-Oncology 2011 Pediatric Neuro-Oncology Basic and Translational Research Conference. New Orleans, LA.
 3. **Reitman ZJ,** Paoella B, Bergthold G, Pelton K, Becker S, Jones R, Herbert Z, Grimmett L, Daley J, Filbin M, Suva M, Goumnerova L, Wright K, Chi S, Kieran M, Regev A, Shalek A, Ligon KL, Beroukhim R, Bandopadhyay P. Resolving transcriptional profiles in BRAF-rearranged pilocytic astrocytoma using single cell RNA sequencing (2018). Oral presentation LGG-13. 1 July. International Society for Pediatric Neuro-Oncology. Denver, CO.
 4. **Reitman ZJ.** Single cell RNA-seq analysis of pediatric low grade gliomas (2018). Low-Grade Gliomas Translational Science Working Group. 12 July. NRG Oncology Semi-Annual Meeting. Philadelphia, PA.
 5. **Reitman ZJ.** Single cell RNA-seq analysis of pediatric low grade gliomas (2019). Low-Grade Gliomas Translational Science Working Group. 8 February. Mitogenic and progenitor gene programs in pilocytic astrocytomas revealed by single cell RNA-seq. NRG Oncology Semi-Annual Meeting. Phoenix, AZ.
 6. **Reitman ZJ.** Enhancing the efficacy of radiation therapy for pediatric brain tumors (2019). Neurobiology of Disease in Children. Special Symposium on Childhood Brain Tumors. 24 Oct. Charlotte, NC.
 7. **Reitman ZJ.** FLASH for brainstem gliomas (2019). Ian's Friends Foundation WhatIFF Symposium. 14 Sept. Atlanta, GA.
- iii. Instructional Courses, workshops, symposiums (National)
 1. **Reitman ZJ.** Profiling metabolomic changes associated with glioma-derived isocitrate dehydrogenase mutations (2011). Practical Applications of Metabolomics Workshop. 6 May. St. Louis, MO.
 2. **Reitman ZJ.** Metabolomics of brain tumors: profiling the effect of isocitrate dehydrogenase mutations in gliomas (2011). Practical Applications of Metabolomics Workshop. 23 Sept. Raleigh, NC.
 3. **Reitman ZJ.** Metabolomics of brain tumors: profiling the effect of isocitrate dehydrogenase mutations in gliomas (2011). Practical Applications of Metabolomics Workshop. 10 Nov. Irvine, CA.

4. **Reitman ZJ.** Metabolomics of brain tumors: profiling the effect of isocitrate dehydrogenase mutations in gliomas (2011). Practical Applications of Metabolomics Workshop. 11 Nov. San Mateo, CA.
 5. **Reitman ZJ.** Profiling metabolomic changes associated with glioma-derived isocitrate dehydrogenase mutations (2012). Practical Applications of Metabolomics Workshop. 7 Sept. Houston, TX.
 6. **Reitman ZJ.** IDH1 Mutation and His Loyal Partners: ATRX, TP53, CIC and FUBP1 in Malignant Gliomas (2012). 11th Annual Frye-Halloran Symposium: Molecular Genetics of Low-Grade Gliomas: Genomic Alterations Guiding Diagnosis and Therapeutic Intervention. 4 Oct. Massachusetts General Hospital, Boston, MA.
 7. **Reitman ZJ.** Profiling metabolomic changes associated with glioma-derived isocitrate dehydrogenase mutations (2013). Practical Applications of Metabolomics Workshop. 1 May. Philadelphia, PA.
 8. **Reitman ZJ.** Profiling metabolomic changes associated with glioma-derived IDH1 mutations (2015). Practical Applications of Metabolomics Workshop. 25 Feb. Boston, MA.
 9. **Reitman ZJ.** Immune infiltrates in BRAF-mutated low grade gliomas profiled by single cell RNA sequencing (2020). Moyle Low Grade Glioma workshop. 19 Feb. Durham, NC.
 10. **Reitman ZJ.** Ultra High Dose Rate FLASH radiation therapy to improve outcomes for pediatric brain tumors (2020). NCI SPORE Mid-Winter Meeting. 21 Feb. Chicago, IL.
 11. **Reitman ZJ.** Ultra High Dose Rate FLASH radiation therapy to improve outcomes for pediatric brain tumors (2020). NCI SPORE monthly WebEx update. 5 Jun. Online.
 12. **Reitman ZJ.** Radiation Therapy in the Treatment of adult primary brain tumors (2020). Radiation Oncology - A Comprehensive Review (directed by Christopher Willett, MD). Oakstone Publishing. 12 Oct. Recorded webinar.
 13. **Reitman ZJ.** Role of the radiation oncologist in treating renal cell carcinoma (2022). Eisai Renal Cell Carcinoma Workshop. (Directed by Alan Herosian). May 10. Durham, NC.
- iv. Posters (National meetings)
1. **Reitman ZJ, Jin G, Cui B, Lopez GY, Yan H.** Characterization of mutant NADP⁺-dependent isocitrate dehydrogenases in glioma development (2009). Poster #15. Days of Mol. Med. Conference. 7-9 May. Boston, MA.
 2. Yan H, Parsons DW, Jin G, **Reitman ZJ**, McLendon R, Reardon DA, Friedman AH, Friedman H, Herndon J, Riggins GJ, Jones S, Kinzler K, Vogelstein B, Velculescu V, Rasheed AB, Kos I, Batinic-Haberle I, Bigner D. IDH1 and IDH2 mutations play a fundamental role in glioma development. (2009). Sub-article 191. Neuro-Oncol. 11(5) 564-699 22-24 Oct. Joint meeting of the Society for Neuro-Oncology and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors. New Orleans, LA.
 3. Yan H., **Reitman ZJ** (presenter), Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Profiling the effects of IDH1 and IDH2 mutants on the glioma cell metabolome. (2011). Poster LB-257. AACR 102nd Annual Meeting. 1-5 April. Orlando, FL.
 4. **Reitman ZJ**, Paoletta B, Bergthold G, Pelton K, Becker S, Jones R, Herbert Z, Grimmert L, Daley J, Filbin M, Suva M, Goumnerova L, Wright K, Chi S, Kieran M, Regev A, Shalek A, Ligon KL, Beroukhir R, Bandopadhyay P. Resolving transcriptional profiles in BRAF-rearranged pilocytic astrocytoma using single cell RNA sequencing. (2018). Radiation Research Society Annual Meeting. Chicago, IL.
 5. Khadka P*, **Reitman ZJ** *, Lu S, Buchan G, Hartley R, Bear H, Georgis Y, Jarmale S, Schoolcraft

K, Miller P, Elizabeth Gonzalez E, Gionet G, Qian K, Melanson R, Keshishian H, Condurat A, Goodale A, Abid T, Piccioni F, Chi S, Carr S, Haas-Kogan D, Ebert BL, Kieran M, Jones C, Ligon KL, Rameen Beroukhim R, Phoenix T*, Bandopadhyay P*. Characterizing the role of *PPM1D* mutations in the pathogenesis of Diffuse Intrinsic Pontine Gliomas (DIPGs) (2020). International Society for Pediatric Neuro Oncology. Dec 13. Online. Accepted.

6. Hariharan S, Kilic C, Bowie M, **Reitman ZJ**, Ashley DM. Epigenetic reprogramming leads to innate immune pathway activation in AT/RT (2020). International Society for Pediatric Neuro Oncology. Dec 13. Online. Accepted.
7. Guerra Garcia ME, Deland K, Luo L, Ma Y, Williams N, Stewart C, Kirsch DG, **Reitman ZJ**. Identification of diffuse midline glioma genotypes that can be radiosensitized by *Atm* deletion *in vivo* (2020). Radiation Research Society Annual Meeting. Oct 15. Online.
8. Guerra Garcia ME, Deland K, Luo L, Ma Y, Williams N, Stewart C, Kirsch DG, **Reitman ZJ**. Dissecting the effect of *Atm* deletion on radiosensitivity in diffuse midline gliomas with H3K27M mutation (2021). Society for Neuro-Oncology Pediatric Neuro-Oncology Research Conference. Jun 12. HGG-16.
9. Stewart CE, Guerra Garcia ME, Deland K, Williams N, Luo L, Ma Y, Kirsch DG, **Reitman ZJ**. Investigating the effect of *Atm* deletion on radiosensitivity of p53-wild type diffuse midline gliomas (2021). Radiation Research Society Annual Meeting. Oct 15. San Juan, Puerto Rico.
10. Weidenhammer L, Guerra Garcia ME, Stewart CE, Williams NT, Luo L, Ma Y, Deland K, Attardi L, Kirsch DG, Reitman ZJ. Investigating the effect of the p53 transactivation domain 1 on tumor suppression of diffuse midline gliomas. Radiation Research Society Annual Meeting.
11. R Regal JA, Guerra García ME, Jain V, Chandramohan V, Ashley DM, Gregory SG, Thompson EM, López GY, **Reitman ZJ***. Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population (2023). Pediatric Society of Neuro Oncology Research Meeting. Washington, DC 23-26 June.

v. Regional presentations and posters

1. **Reitman ZJ**. Shooting down glioma's driver mutation and partners in cancer crime (2012). 3rd Annual Basic Science Day. 16 Oct. Duke University School of Medicine, Durham, NC.
2. **Reitman ZJ**. Enzyme redesign guided by cancer mutations (2013). 1st Annual Tobacco Road Medical Research Symposium. 4 Nov. University of North Carolina School of Medicine, Chapel Hill, NC.
3. **Reitman ZJ**. Resolving transcriptional profiles in BRAF-duplicated pilocytic astrocytomas using single cell RNA-seq. (2018). Dana-Farber Cancer Institute, Department of Cancer Biology Friday Seminar. 21 Sept.
4. **Reitman ZJ**. Mitogenic and progenitor programs in single pilocytic astrocytoma cells. (2018). Dana-Farber Cancer Institute Data Science Club. 19 Oct. Boston, MA.
5. **Reitman ZJ**. Mitogenic and progenitor programs in pilocytic astrocytomas revealed by single cell RNA sequencing. (2018). Brigham and Women's Hospital Neuro Oncology Seminar Series. 26 Oct. Boston, MA.
6. **Reitman ZJ**. Mitogenic and progenitor programs in pilocytic astrocytomas revealed by single cell RNA sequencing. (2018). Boston Children's Hospital Department of Hematology Oncology Lecture Series. 1 Nov. Boston, MA.

7. Khadka P, **Reitman ZJ** (co-presenters). Characterizing the role of PPM1D mutations in the pathogenesis of diffuse intrinsic pontine gliomas. (2018). Dana-Farber Cancer Institute Monday Neuro-Oncology Lecture Series. 17 Dec. Boston, MA.

Clinical activity:

2020-present Duke University Hospital, Central Nervous System Radiation Oncology, one day weekly, 20% professional effort commitment.

Participation in academic and administrative activities of the University and Medical Center

i. Administrative positions

None.

ii. Committees

1. Duke Center for Brain and Spine Metastases Biobanking Committee
2. Duke Department of Radiation Oncology CNS Research Committee
3. Executive Committee, Brain Tumor Omics Program at the Preston Robert Tisch Brain Tumor Center at Duke
4. Medical Scientist Training Program (MSTP) Admissions Committee 2023-2024

iii. Leadership positions

Director of Reitman brain tumor research group.

07/24/2023



Date

Signature

Personal Information

Faculty members' preferred familiar name: Zach

Home address: 1102 Birchbark Rd, Durham, NC 27705

Home Phone # 484-716-8416

Email address: zjr@duke.edu

Spouse name: Denise Di Pong, MD, MPH (Assistant Professor of Medicine at Duke)